Changing the Subject (Part 5): A Lesson From The Past
This article was originally published in RPM Report
Rather than try to “win” the drug pricing debate, the biopharma sector may be better served by coming up with new ideas to change the subject. We outlined our case for taking this approach – and the model for ideas that serve that goal – here. Today, a reader reminds us that the Prescription Drug User Fee Act is an example of one time the approach seemed to work in the past.